United Therapeutics announced positive Phase 1 results for miroliverELAP, an external liver assist device developed by its subsidiary Miromatrix Medical. The study of five acute liver failure patients met its primary endpoint of survival with no unexpected serious adverse events. The stock is up 0.44% in premarket trading, with analysts expecting strong Q4 earnings growth.

MannKind Corporation announced strong 2026 growth catalysts including FDA decisions on Afrezza label updates and pediatric indications, FUROSCIX ReadyFlow Autoinjector approval, and pipeline progress with Nintedanib DPI and Bumetanib DPI. The company closed 2025 with record Q4 revenue exceeding $100 million and completed the acquisition of scPharmaceuticals.

Summit Street Capital Management initiated a new $27.3 million position in Weatherford International during Q3, representing 3.74% of their reportable assets under management, signaling potential confidence in the oilfield services company's future prospects.

Summit Street Capital Management initiated a $25.3 million position in Signet Jewelers, representing 3.5% of its reportable assets, signaling potential value in the company's margin recovery and strategic performance.

Nepsis Inc. fully sold its entire stake in CyberArk Software during Q3 2025, liquidating 34,236 shares worth approximately $13.93 million, potentially due to the stock's high valuation and recent price surge.

The artificial lung market is projected to grow from $2.78 billion in 2025 to $7.05 billion by 2034, with a 10.84% CAGR. North America dominates the market, driven by rising respiratory disease prevalence and technological advancements in medical devices.

Despite ongoing global tensions, the stock market showed resilience during the holiday season, with the S&P 500 and Nasdaq rising. Three high-growth stocks - PDD Holdings, Alphabet, and United Therapeutics - demonstrated strong performance and potential for continued gains through year-end.

MannKind reported Q2 2025 revenue of $76.5 million, slightly missing analyst estimates. The company saw growth in Afrezza inhaled insulin sales and Tyvaso DPI royalties, while increasing R&D and marketing expenses.

Rosen Law Firm is pursuing a securities class action lawsuit against 3D Systems Corporation, alleging the company made false or misleading statements about its business performance and partnership impacts during the period of August 13, 2024 to May 12, 2025.

Rosen Law Firm is notifying investors of a securities class action lawsuit against 3D Systems Corporation for allegedly making false and misleading statements about business performance and partnership impacts during August 2024 to May 2025.

Rosen Law Firm is notifying investors of a securities class action lawsuit against 3D Systems Corporation for potentially misleading statements about business performance and partnership impacts during August 2024 to May 2025.

Several large-cap stocks, including AppLovin, Chewy, and Carvana, were among the top losers last week. The declines were attributed to factors such as weak earnings guidance, lower-than-expected sales outlook, and bearish options activity.